FDA Approves New Corticosteroid Treatment Option for DMD Patients | BioSpace
Pictured: A boy sitting in a wheelchair on a beach/iStock, ChiccoDodiFC The FDA on Thursday approved Santhera Pharmaceuticals’ new corticosteroid vamorolone, now marketed under the brand name Agamree, for the treatment of Duchenne muscular dystrophy. The announcement was made by Florida-based Catalyst Pharmaceuticals, which paid $90 million upfront in June… Continue Reading FDA Approves New Corticosteroid Treatment Option for DMD Patients | BioSpace